GMAB
Genmab AS
34.80$
+0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 93.7% | 93.9% | 93.7% | 56.8% | 59.8% | 60.8% | 60.5% | 60.5% | 63.7% | 22.4% | 20.8% | 22.4% | |
| 40.5% | 42.1% | 40.0% | 11.2% | 16.0% | 21.5% | 20.0% | 20.0% | 25.1% | 13.3% | 12.3% | 12.0% | |
| 78.1% | 79.7% | 80.7% | 40.7% | 43.7% | 46.1% | 44.8% | 44.8% | 48.6% | 13.3% | 12.3% | 12.0% | |
| 15.4% | 14.0% | 12.8% | 16.0% | 15.9% | 14.6% | 15.4% | 15.4% | 14.9% | 8.9% | 8.3% | 10.2% | |
| 0.2% | 0.2% | 0.3% | 0.1% | 0.2% | 0.1% | 0.2% | 0.2% | 0.2% | 0.1% | 0.2% | 0.1% | |
| 4.7% | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0% | 6.9% | 6.5% | 6.1% | 5.5% | 5.5% | 5.5% | 5.1% | 2.8% | 2.9% | 2.8% | |
| 0.3% | 0.3% | 0.1% | 31.1% | 29.0% | 26.9% | 27.1% | 27.1% | 24.9% | 70.9% | 72.3% | 70.9% | |
| 11.7% | 10.4% | 11.4% | 19.8% | 19.5% | 19.9% | 18.0% | 18.0% | 18.1% | 54.6% | 54.1% | 52.4% | |
| 8.2% | 7.0% | 7.5% | 11.3% | 11.6% | 11.6% | 9.7% | 9.7% | 10.6% | 11.1% | 9.5% | 9.1% | |
| 0.2% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 2.3% | 2.5% | 2.5% | |
| 6.6% | 6.5% | 9.3% | – | – | – | – | – | – | 8.3% | 7.0% | – | |
| – | 1.9% | 2.5% | 2.4% | 2.3% | 2.0% | – | – | – | 38.9% | 39.9% | 38.7% | |
| 88.3% | 89.6% | 88.6% | 80.2% | 80.5% | 80.1% | 82.0% | 82.0% | 81.9% | 45.4% | 45.9% | 47.6% | |
| 52.4% | 53.9% | 54.0% | 47.0% | 49.5% | 51.4% | 55.7% | 55.7% | 57.4% | 31.8% | 33.0% | 35.3% | |
| 1.9% | 1.9% | 1.8% | 1.7% | 1.6% | 1.4% | 10.6% | 9.6% | 8.8% | 5.2% | 5.2% | 4.9% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.